<?xml version='1.0' encoding='utf-8'?>
<document id="25342921"><sentence text="Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study."><entity charOffset="18-27" id="DDI-PubMed.25342921.s1.e0" text="ezogabine" /><entity charOffset="28-38" id="DDI-PubMed.25342921.s1.e1" text="retigabine" /><entity charOffset="66-73" id="DDI-PubMed.25342921.s1.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.25342921.s1.e0" e2="DDI-PubMed.25342921.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s1.e0" e2="DDI-PubMed.25342921.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s1.e0" e2="DDI-PubMed.25342921.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s1.e1" e2="DDI-PubMed.25342921.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s1.e1" e2="DDI-PubMed.25342921.s1.e2" /></sentence><sentence text="The potential for ezogabine/retigabine (EZG/RTG) and its N-acetyl metabolite (NAMR) to inhibit the transporter protein P-glycoprotein-(P-gp)-mediated digoxin transport was tested in vitro"><entity charOffset="18-27" id="DDI-PubMed.25342921.s2.e0" text="ezogabine" /><entity charOffset="28-38" id="DDI-PubMed.25342921.s2.e1" text="retigabine" /><entity charOffset="40-43" id="DDI-PubMed.25342921.s2.e2" text="EZG" /><entity charOffset="44-47" id="DDI-PubMed.25342921.s2.e3" text="RTG" /><entity charOffset="57-65" id="DDI-PubMed.25342921.s2.e4" text="N-acetyl" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e0" e2="DDI-PubMed.25342921.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e0" e2="DDI-PubMed.25342921.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e0" e2="DDI-PubMed.25342921.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e0" e2="DDI-PubMed.25342921.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e0" e2="DDI-PubMed.25342921.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e1" e2="DDI-PubMed.25342921.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e1" e2="DDI-PubMed.25342921.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e1" e2="DDI-PubMed.25342921.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e1" e2="DDI-PubMed.25342921.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e2" e2="DDI-PubMed.25342921.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e2" e2="DDI-PubMed.25342921.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e2" e2="DDI-PubMed.25342921.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e3" e2="DDI-PubMed.25342921.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s2.e3" e2="DDI-PubMed.25342921.s2.e4" /></sentence><sentence text=" EZG/RTG did not inhibit P-gp"><entity charOffset="1-8" id="DDI-PubMed.25342921.s3.e0" text="EZG" /><entity charOffset="5-12" id="DDI-PubMed.25342921.s3.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s3.e0" e2="DDI-PubMed.25342921.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s3.e0" e2="DDI-PubMed.25342921.s3.e1" /></sentence><sentence text=" However, NAMR inhibited P-gp in a concentration-dependent manner" /><sentence text=" Based on these in vitro results, NAMR had the potential to inhibit P-gp at therapeutic doses of EZG/RTG (600-1,200 mg/day)"><entity charOffset="97-99" id="DDI-PubMed.25342921.s5.e0" text="EZG" /><entity charOffset="101-103" id="DDI-PubMed.25342921.s5.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s5.e0" e2="DDI-PubMed.25342921.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s5.e0" e2="DDI-PubMed.25342921.s5.e1" /></sentence><sentence text=" As digoxin has a narrow therapeutic index, inhibition of digoxin clearance may have an impact on its safety"><entity charOffset="4-11" id="DDI-PubMed.25342921.s6.e0" text="digoxin" /><entity charOffset="58-65" id="DDI-PubMed.25342921.s6.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.25342921.s6.e0" e2="DDI-PubMed.25342921.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s6.e0" e2="DDI-PubMed.25342921.s6.e1" /></sentence><sentence text="" /><sentence text="An open-label, single-center, two session, fixed-sequence study was conducted to assess the effect of co-administration of therapeutic doses of EZG/RTG on digoxin pharmacokinetics in healthy adults"><entity charOffset="155-162" id="DDI-PubMed.25342921.s8.e0" text="digoxin" /><entity charOffset="144-150" id="DDI-PubMed.25342921.s8.e1" text="EZG" /><entity charOffset="148-154" id="DDI-PubMed.25342921.s8.e2" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s8.e1" e2="DDI-PubMed.25342921.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s8.e1" e2="DDI-PubMed.25342921.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s8.e1" e2="DDI-PubMed.25342921.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s8.e2" e2="DDI-PubMed.25342921.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s8.e2" e2="DDI-PubMed.25342921.s8.e0" /></sentence><sentence text=" In session 1, subjects received a single dose of digoxin 0"><entity charOffset="50-57" id="DDI-PubMed.25342921.s9.e0" text="digoxin" /></sentence><sentence text="25 mg" /><sentence text=" In session 2, EZG/RTG was up-titrated over 6 weeks"><entity charOffset="15-21" id="DDI-PubMed.25342921.s11.e0" text="EZG" /><entity charOffset="19-25" id="DDI-PubMed.25342921.s11.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s11.e0" e2="DDI-PubMed.25342921.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s11.e0" e2="DDI-PubMed.25342921.s11.e1" /></sentence><sentence text=" Digoxin 0"><entity charOffset="1-8" id="DDI-PubMed.25342921.s12.e0" text="Digoxin" /></sentence><sentence text="25 mg was co-administered at EZG/RTG steady-state doses of 600, 900, and, based on tolerability, 1,050/1,200 mg/day"><entity charOffset="29-35" id="DDI-PubMed.25342921.s13.e0" text="EZG" /><entity charOffset="33-39" id="DDI-PubMed.25342921.s13.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s13.e0" e2="DDI-PubMed.25342921.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s13.e0" e2="DDI-PubMed.25342921.s13.e1" /></sentence><sentence text=" Blood samples were collected over 144 hours for determination of digoxin, EZG/RTG, and NAMR concentrations"><entity charOffset="66-73" id="DDI-PubMed.25342921.s14.e0" text="digoxin" /><entity charOffset="75-81" id="DDI-PubMed.25342921.s14.e1" text="EZG" /><entity charOffset="79-85" id="DDI-PubMed.25342921.s14.e2" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s14.e0" e2="DDI-PubMed.25342921.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s14.e0" e2="DDI-PubMed.25342921.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s14.e0" e2="DDI-PubMed.25342921.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s14.e1" e2="DDI-PubMed.25342921.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s14.e1" e2="DDI-PubMed.25342921.s14.e2" /></sentence><sentence text=" Urine samples were collected over 48 hours for determination of digoxin concentrations"><entity charOffset="65-72" id="DDI-PubMed.25342921.s15.e0" text="digoxin" /></sentence><sentence text="" /><sentence text="Of 30 subjects enrolled, 29 were included in the pharmacokinetic analysis" /><sentence text=" Compared with digoxin alone, co-administration with EZG/RTG led to small increases in the digoxin plasma area under the concentration-time curve (AUC)0-120 at doses of 600, 900, and 1,050/1,200 mg (geometric mean ratio 1"><entity charOffset="15-22" id="DDI-PubMed.25342921.s18.e0" text="digoxin" /><entity charOffset="91-98" id="DDI-PubMed.25342921.s18.e1" text="digoxin" /><entity charOffset="53-59" id="DDI-PubMed.25342921.s18.e2" text="EZG" /><entity charOffset="57-63" id="DDI-PubMed.25342921.s18.e3" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e0" e2="DDI-PubMed.25342921.s18.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e0" e2="DDI-PubMed.25342921.s18.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e0" e2="DDI-PubMed.25342921.s18.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e0" e2="DDI-PubMed.25342921.s18.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e2" e2="DDI-PubMed.25342921.s18.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e2" e2="DDI-PubMed.25342921.s18.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e2" e2="DDI-PubMed.25342921.s18.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e3" e2="DDI-PubMed.25342921.s18.e3" /><pair ddi="false" e1="DDI-PubMed.25342921.s18.e3" e2="DDI-PubMed.25342921.s18.e1" /></sentence><sentence text="08, 90% confidence interval [CI] 1" /><sentence text="01-1" /><sentence text="15; 1" /><sentence text="18, 90% CI 1" /><sentence text="10-1" /><sentence text="27; 1" /><sentence text="13, 90% CI 1" /><sentence text="05-1" /><sentence text="21, respectively)" /><sentence text=" Safety was consistent with previous repeat-dose studies of EZG/RTG in healthy subjects"><entity charOffset="60-62" id="DDI-PubMed.25342921.s28.e0" text="EZG" /><entity charOffset="64-66" id="DDI-PubMed.25342921.s28.e1" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s28.e0" e2="DDI-PubMed.25342921.s28.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s28.e0" e2="DDI-PubMed.25342921.s28.e1" /></sentence><sentence text="" /><sentence text="Co-administration of EZG/RTG across the therapeutic range resulted in small, non-dose-dependent and non-clinically relevant increases in digoxin systemic exposure, suggesting that digoxin dose adjustment is not necessary"><entity charOffset="180-187" id="DDI-PubMed.25342921.s30.e0" text="digoxin" /><entity charOffset="21-27" id="DDI-PubMed.25342921.s30.e1" text="EZG" /><entity charOffset="25-31" id="DDI-PubMed.25342921.s30.e2" text="RTG" /><pair ddi="false" e1="DDI-PubMed.25342921.s30.e1" e2="DDI-PubMed.25342921.s30.e1" /><pair ddi="false" e1="DDI-PubMed.25342921.s30.e1" e2="DDI-PubMed.25342921.s30.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s30.e1" e2="DDI-PubMed.25342921.s30.e0" /><pair ddi="false" e1="DDI-PubMed.25342921.s30.e2" e2="DDI-PubMed.25342921.s30.e2" /><pair ddi="false" e1="DDI-PubMed.25342921.s30.e2" e2="DDI-PubMed.25342921.s30.e0" /></sentence><sentence text="" /></document>